Stockscreener 앱 받기
42.88
1.22%
-0.53
시간 외 거래:
43.43
0.55
+1.28%
전일 마감가:
$43.41
열려 있는:
$43.525
하루 거래량:
3.96M
Relative Volume:
0.86
시가총액:
$34.80B
수익:
$28.43B
순이익/손실:
$1.16B
주가수익비율:
29.66
EPS:
1.4457
순현금흐름:
$1.26B
1주 성능:
-3.40%
1개월 성능:
-5.32%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$42.65
$43.75
1주일 범위
$42.53
$44.53
52주 변동 폭
$38.50
$50.88
Medline Inc Stock (MDLN) Company Profile
명칭
Medline Inc
전화
847-949-3000
주소
3 LAKES DRIVE, NORTHFIELD
Compare MDLN vs ISRG, BDX, ALC, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDLN
Medline Inc
|
42.88 | 35.23B | 28.43B | 1.16B | 1.26B | 1.4457 |
|
ISRG
Intuitive Surgical Inc
|
485.85 | 175.28B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
163.88 | 47.07B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
80.65 | 39.90B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
RMD
Resmed Inc
|
247.11 | 36.85B | 5.40B | 1.49B | 1.78B | 10.12 |
Medline Inc Stock (MDLN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-05 | 개시 | Tigress Financial | Buy |
| 2026-01-21 | 재확인 | BTIG Research | Buy |
| 2026-01-12 | 개시 | Citigroup | Buy |
| 2026-01-12 | 개시 | Deutsche Bank | Hold |
| 2026-01-12 | 개시 | Evercore ISI | Outperform |
| 2026-01-12 | 개시 | Goldman | Buy |
| 2026-01-12 | 개시 | JP Morgan | Overweight |
| 2026-01-12 | 개시 | Jefferies | Buy |
| 2026-01-12 | 개시 | Leerink Partners | Outperform |
| 2026-01-12 | 개시 | Mizuho | Outperform |
| 2026-01-12 | 개시 | Morgan Stanley | Overweight |
| 2026-01-12 | 개시 | Piper Sandler | Overweight |
| 2026-01-12 | 개시 | RBC Capital Mkts | Outperform |
| 2026-01-12 | 개시 | Robert W. Baird | Outperform |
| 2026-01-12 | 개시 | Rothschild & Co Redburn | Neutral |
| 2026-01-12 | 개시 | Stifel | Buy |
| 2026-01-12 | 개시 | TD Cowen | Buy |
| 2026-01-12 | 개시 | Truist | Buy |
| 2026-01-12 | 개시 | UBS | Buy |
| 2026-01-12 | 개시 | Wells Fargo | Equal Weight |
| 2026-01-12 | 개시 | William Blair | Outperform |
| 2026-01-12 | 개시 | Wolfe Research | Outperform |
모두보기
Medline Inc 주식(MDLN)의 최신 뉴스
Medline (MDLN) Q4 net sales rise 14.8% to $7.8B following completion of IPO - MSN
Medline (MDLN) Q4 Net Sales Rise 14.8% to $7.8B Following Completion of IPO - Insider Monkey
Medline Awards Distribution Center of the Year and SAFE Awards - marketscreener.com
Medline stock price target raised to $60 by Tigress Financial - Investing.com
Medline prices $3B secondary offering at $41 per share - MSN
Medline stock price target reaffirmed at $55 by BTIG - Investing.com
Medline Inc. announces pricing of secondary offering of class A common stock - Sahm
Medline’s buyout firm backers raise $3.1B in share sale - Crain's Chicago Business
Medline’s PE owners cash out US$3.1bn in early lockup release - ifre.com
Medline Secondary Common Stock Offering Prices; Shares Down Pre-Bell - marketscreener.com
Medline stockholders price secondary offering at $41 per share By Investing.com - Investing.com Australia
Medline stockholders price secondary offering at $41 per share - Investing.com
Medline’s Buyout Firm Backers Raise $3.1 Billion in Share Sale - Bloomberg.com
Medline Inc. Announces Pricing Of Secondary Offering Of Class A Common Stock - TradingView
Shareholders of the American Medline intend to sell shares worth $ 3.4 billion - AKM.RU
Ear Syringe Market Set to Witness Rapid Growth Through 2033 | - openPR.com
Medline Backers Launch $3.4B Secondary Sale Near Chicago - Hoodline
Blackstone, Carlyle, Hellman & Friedman Offer 75M Shares For MedlineMedline (NASDAQ:MDLN) - Benzinga
Medline’s PE backers start stake sale worth $3.4 billion - Crain's Chicago Business
Medline Shareholders Seek $3.4 Billion Stake Sale - Transport Topics
Medline’s PE Backers Start Stake Sale Worth $3.4 Billion - Bloomberg
Medline stockholders launch 75 million share offering - Investing.com
Medline shares fall 4.4% as major investors launch secondary offering By Investing.com - Investing.com Nigeria
Medline stockholders launch 75 million share offering By Investing.com - Investing.com Canada
Medline announces $3.6B secondary offering from private equity firms - MassDevice
Medline Inc. announces launch of secondary offering of Class A common stock - GlobeNewswire
Form S-1 Medline Inc. - StreetInsider
USA Herald - USA Herald
The 20+ Club: Ron Woosley - Medline Newsroom
Medline expands AI platform and warehouse robotics - Digital Commerce 360
Medline Inc.: Fundamental Analysis and Financial Ratings | MDLN | US58507V1070 - marketscreener.com
The Analyst Verdict: Medline In The Eyes Of 29 Experts - Benzinga
Wells Fargo & Company Increases Medline (NASDAQ:MDLN) Price Target to $47.00 - MarketBeat
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Medline, Inc. Class A (MDLN) and Silence Therapeutics (SLN) - The Globe and Mail
Medline Inc (MDLN) Q4 2025 Earnings Call Highlights: Record Sales and Strategic Innovations ... By GuruFocus - Investing.com Canada
Medline Analysts Boost Their Forecasts Following Q4 Results - Benzinga
Medline (NASDAQ:MDLN) Given New $54.00 Price Target at BMO Capital Markets - MarketBeat
Medline boasts $2.4B in new customer signings in 2025 - HME News
Wolfe Research raises Medline stock price target on revenue beat By Investing.com - Investing.com India
Wolfe Research raises Medline stock price target on revenue beat - Investing.com
CEO of Northfield-based Medline talks tariffs, IPO following company’s first earnings call - Chicago Tribune
Analyst recommendations: Spotify, Gartner, Godaddy, Medline, Moderna… - marketscreener.com
Evercore ISI Maintains Outperform on Medline Inc (MDLN) Feb 25 2026 - Meyka
Medline's first quarter as a public company ends with rising sales, dip in income - Crain's Chicago Business
Medline Inc. SEC 10-K Report - TradingView
Stifel raises Medline stock price target to $55 on strong results - Investing.com
Medline Q4 Earnings Call Highlights - MarketBeat
Evercore ISI raises Medline stock price target on strong momentum By Investing.com - Investing.com South Africa
Evercore ISI raises Medline stock price target on strong momentum - Investing.com
Robust Q4 Beat and Underappreciated 2026 Upside Support Buy Rating on Medline - TipRanks
Medline Inc (MDLN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.30%
자본화:
|
볼륨(24시간):